genOway

genOway’s GLP-1R humanized mouse model allows for the efficacy assessment and MoA investigation of GLP-1R-targeting compounds, making it a key tool in testing treatments for various metabolic disorders 👉 https://lnkd.in/eSasDAdf 📰 In an article published in Nature Medicine, Pfizer used a GLP-1R humanized model designed by genOway to test Danuglipron, a human specific GLP-1R agonist for treating type 2 diabetes and obesity, and observed promising results, such as a decrease in blood glucose levels in mice following treatment, helping it move to clinical trials 👉 https://lnkd.in/eHxJ7WJm #GLP1 #type2diabetes #preclinicalmodels

AstraZeneca presented their latest research with the poster ‘AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens’ at Society for Immunotherapy of Cancer (SITC) of Cancer in Houston, TX 👉 https://lnkd.in/gG8YYaiR 🔬 In this poster, AstraZeneca used our Pan hCD3 mouse model to assess the efficacy of their T-cell engager, AZD5863, in reshaping the tumor microenvironment and in inhibiting tumor growth in mono- or combotherapy, enabling it to move to clinical trials 👉 https://lnkd.in/g8s8EmTK #sitc2024 #preclinicalresearch #preclinicalservices

📢 We will be attending the 13th annual Tumour Models London Summit 2024 from December 4-5, 2024! 👉 https://lnkd.in/enjs5umT On Wednesday, December 4, 2024 at 1:30 p.m. GMT, Kader Thiam, our Senior Vice President - Discovery, Preclinical Models and Services, will give a presentation titled "Presence of myeloid and lymphoid cells are key for translational tumor biology, efficacy and safety assessment in humanized mouse models" The presentation will focus on: ▶ Outlining #BRGSF-HIS mice: a CD34+-reconstituted model with functional human lymphoid and myeloid compartments without side effects ▶ Investigating human immune cell recruitment into tumor microenvironment ▶ Studying myeloid cell functionality and their contribution to translatable safety assessment of therapies Read more on the BRGSF-HIS model here 👉 https://lnkd.in/ex9U5-sv #preclinicalmodels #cancerresearch #preclinicalservices

At Society for Immunotherapy of Cancer (SITC) 2024 in Houston, TX, ANAVEON AG presented their new scientific poster: ‘ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor specific T cells by acting in the tumor microenvironment and draining lymph nodes’ 👉 https://lnkd.in/ezQcjfCg   📰 In this poster, Anaveon used our hPD-1 mouse model to assess the efficacy and MoA of their αPD-1/IL-2Rβ/γ bispecific antibody, ANV600, advancing ANV600 to clinical trials 👉  https://lnkd.in/eE4rnVRG    #sitc2024 #preclinicalresearch #preclinicalservices

During the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting in Houston, TX, Teva Pharmaceuticals unveiled a new poster titled ‘Preclinical In Vivo Characterization of the Anti-tumor Activity of a Non-blocking PD-1 Antibody Fused to Attenuated IL-2’ 👉 https://lnkd.in/ePf9f5QJ   📰 In this poster, Teva Pharmaceuticals used our CD34+-reconstituted #BRGSF-HIS mouse model, featuring functional human myeloid and lymphoid compartments, to analyze the composition of the tumor microenvironment (TME) after treatment with their anti-PD-1-IL-2 construct, TEV-56278, and its efficacy in reducing tumor burden 👉 https://lnkd.in/ehYTzJcx #sitc2024 #preclinicalresearch #preclinicalservices

At the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting in Houston, TX, our team presented the new scientific poster ‘Assessment of γδ T-cell therapies in humanized mice’ 👉  https://lnkd.in/eTPxBP3t    In this poster, we demonstrate that functional γδ T-cells develop in our CD34+-reconstituted #BRGSF-HIS mouse model, featuring functional human myeloid and lymphoid compartments, making it a useful tool to assess therapies targeting this cell population 👉 https://lnkd.in/g5qpbJTU   #sitc2024 #preclinicalresearch #preclinicalservices

🔬We unveiled a new scientific poster at the Society for Immunotherapy of Cancer (SITC) annual meeting in Houston, TX, titled ‘Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice’ 👉 https://lnkd.in/gPcQKbnv This poster demonstrates that our CD34+-reconstituted #BRGSF-HIS mouse model, featuring functional human myeloid and lymphoid compartments, is a valuable tool to investigate immune cell infiltration in the TME, enabling the translatable assessment of the efficacy and MOA of immunotherapies targeting myeloid and lymphoid cells 👉 https://lnkd.in/g5qpbJTU #sitc2024 #preclinicalresearch #preclinicalservices

📢 Our team of Scientific Experts and Business Developers is attending Society for Immunotherapy of Cancer (SITC) in Houston, TX; come see us at booth #647! 👉 https://lnkd.in/eabsGCmN Let us discuss how our preclinical models and solutions of high predictability can help you achieve your research needs. 🔬✔️ Don’t miss our three poster presentations on: 📅 Friday, 8 November ▶️ Poster #937: ‘Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in #BRGSF-HIS mice’ ▶️ Poster #877: ‘Assessment of γδ T-cell therapies in humanized mice’ Learn more on our BRGSF-HIS model here 👉 https://lnkd.in/gx6wsyku 📅 Saturday, 9 November Poster #1446: ‘Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies’ Learn more on our FcγR model here 👉 https://lnkd.in/g_M2PbsB See you at the conference! #sitc2024 #preclinicalresearch #preclinicalservices

🌟 From 24 to 27 October, 2024, our teams participated to the 16th Annual Meeting of the Chinese Society for Immunology (CSI) which hosted over 4,000 international attendees in Hangzhou, China. 📅 During the conference: ▶️ Alexandre Fraichard, genOway's CEO, gave a presentation on the development of a double humanized immune system and liver in mouse as a new tool for drug development and safety assessment ▶️ Claire S. Santos, Senior Scientific Business Developer at genOway, presented the benefits of assessing compound safety with our highly predictive CD34+-reconstituted #BRGSF-HIS mouse model with functional human lymphoid and myeloid compartments 👉 https://lnkd.in/eYSxu6CH This was another great opportunity to work hand-in-hand with our genOway Shanghai team to present genOway’s scientific excellence and our highly predictive preclinical models to immunologists in China! #genowayshanghai #preclinicalmodels #preclinicalservices

📢 We will be participating to the upcoming Society for Immunotherapy of Cancer (SITC) meeting in Houston, TX from 6-10 November, 2024 👉 https://lnkd.in/eabsGCmN Our team of Scientific Business Developers and Experts would be thrilled to meet you at booth #647 to discuss how our preclinical solutions could help you in your research needs. If you’d like to book a 1-on-1 meeting, please contact us here 👉 https://lnkd.in/euwu4Ga3 To learn more on our preclinical models, stop by one of our three poster presentations on: 📅 Friday, 8 November 👉 Poster #937: ‘Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice’ 👉 Poster #877: ‘Assessment of γδ T-cell therapies in humanized mice’ 📅 Saturday, 9 November 👉Poster #1446: ‘Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies’ Don't miss this opportunity to meet us!   #sitc2024 #preclinicalresearch #preclinicalservices